Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Teva Pharmaceutical Industries Ltd (TEVA)

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,685,127
  • Shares Outstanding, K 1,092,189
  • Annual Sales, $ 16,887 M
  • Annual Income, $ -998,000 K
  • 60-Month Beta 1.60
  • Price/Sales 0.84
  • Price/Cash Flow 3.32
  • Price/Book 0.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.48
  • Number of Estimates 6
  • High Estimate 0.53
  • Low Estimate 0.37
  • Prior Year 0.57
  • Growth Rate Est. (year over year) -15.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.72 +28.91%
on 05/04/20
13.23 -5.29%
on 05/28/20
+1.46 (+13.19%)
since 04/29/20
3-Month
6.25 +100.48%
on 03/18/20
13.23 -5.29%
on 05/28/20
+1.00 (+8.67%)
since 02/28/20
52-Week
6.07 +106.43%
on 08/15/19
13.76 -8.94%
on 02/12/20
+2.83 (+29.18%)
since 05/29/19

Most Recent Stories

More News
Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

TEVA : 12.53 (-3.02%)
The Global Pulmonary Drug Delivery Devices Market is expected to grow from USD 39,125.13 Million in 2018 to USD 56,236.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.31%

, /PRNewswire/ -- The Global Pulmonary Drug Delivery Devices Market is expected to grow from in 2018 to by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.31%. Read the full report: The...

GSK : 41.92 (+0.91%)
MRK : 80.72 (+2.13%)
NVS : 87.43 (+1.33%)
OMRNY : 66.7100 (-1.93%)
TEVA : 12.53 (-3.02%)
Global Over-the-counter Drugs market is Expected to Reach $237.66 Billion by 2027 - Latest Market Research Report by Stratistics MRC

, /PRNewswire/ --

ABT : 94.92 (+3.06%)
GSK : 41.92 (+0.91%)
NVS : 87.43 (+1.33%)
PG : 115.92 (-0.12%)
RBGLY : 17.8795 (+1.99%)
TEVA : 12.53 (-3.02%)
Asthma Treatment Market to Reach USD 26.01 Billion by 2027; Rising Incidence Of Respiratory Diseases to Augment Growth, states Fortune Business Insights(TM)

The global asthma treatment market size is expected to reach USD 26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period. The growing incidence of respiratory diseases such of chronic...

GSK : 41.92 (+0.91%)
MRK : 80.72 (+2.13%)
NVS : 87.43 (+1.33%)
TEVA : 12.53 (-3.02%)
Global Sustained Release Coatings Market Outlook 2020-2025 by Polymer Material Type, Application, Substrate Type, Region and Company

, /PRNewswire/ -- The report has been added to offering.

BASFY : 13.5900 (-1.81%)
CORI : 12.68 (+0.24%)
GSK : 41.92 (+0.91%)
NVS : 87.43 (+1.33%)
PFE : 38.19 (+0.03%)
TEVA : 12.53 (-3.02%)
VRX.TO : 30.80 (-3.33%)
Acute Kidney Injury Treatment Market Present And Upcoming Trends With COVID 19 Impact Study | Novartis AG, Pfizer Inc, Ipsen SA

MarketResearch.Biz published a new industry research report “Acute Kidney Injury Treatment Market” in its database. This is a latest report, including the present COVID-19 impact and future effect on...

CNAT : 0.5560 (+0.18%)
IPSEY : 19.9200 (unch)
MRK : 80.72 (+2.13%)
NVS : 87.43 (+1.33%)
PFE : 38.19 (+0.03%)
TEVA : 12.53 (-3.02%)
VRX.TO : 30.80 (-3.33%)
Teva Announces Virtual 2020 Annual Meeting of Shareholders

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) ("Teva"), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of...

TEVA : 12.53 (-3.02%)
Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY(R) (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY(R) (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress...

TEVA : 12.53 (-3.02%)
Can Teva (TEVA) Return to Growth in This Year or Next?

Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.

TEVA : 12.53 (-3.02%)
GILD : 77.83 (+3.33%)
MRK : 80.72 (+2.13%)
LLY : 152.95 (+1.53%)
Teva to Present New AJOVY(R) (fremanezumab) Analyses and Latest COPAXONE(R) Data (glatiramer acetate injection) at European Academy of Neurology Congress

--GALA open-label extension study evaluates 7-year efficacy and safety results of COPAXONE

TEVA : 12.53 (-3.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade TEVA with:

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

2nd Resistance Point 13.31
1st Resistance Point 12.92
Last Price 12.53
1st Support Level 12.21
2nd Support Level 11.89

See More

52-Week High 13.76
Last Price 12.53
Fibonacci 61.8% 10.82
Fibonacci 50% 9.91
Fibonacci 38.2% 9.01
52-Week Low 6.07

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar